Navigation Links
PET scan can non invasively measure early assessment of treatment for common type of breast cancer
Date:5/26/2009

Seattle Non-invasive imaging can measure how well patients with the most common form of breast cancer - estrogen receptor positive type - respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting next week.

Using Positron Emission Tomography (PET) scanning and a glucose analogue called FDG, a research team led by Hannah Linden, M.D. and David Mankoff M.D., of the Seattle Cancer Care Alliance and the University of Washington, scanned 21 patients before and after two weeks of aromatase inhibitor therapy. Many of the patients also underwent a needle biopsy as a control measure to compare the two techniques.

The results 16 of the 21 patients had a greater than 20 percent decline in FDG values "paralleled perfectly" earlier work done by UK-based researchers who used needle biopsies to measure whether the proliferation of cancer cells was slowed by therapy, according to Linden, who is a breast cancer oncologist.

"Our findings are exciting because they suggest that we can measure a patient's response to therapy noninvasively, and PET scanning provides us simultaneous quantitative metabolic measurements at multiple tumor sites," Linden said. "PET has the potential to be a powerful tool to help doctors make important treatment decisions in as little as two weeks instead of two or more months."

It's common for patients with estrogen receptor positive cancer to a bone-dominant type yet they have remained largely unstudied in clinical trials because they are very difficult to image, according to Linden. "Our work allowed us to study a common problem in a way that's not been done before and to help more people," she said. "More work needs to be done but in my mind this was a homerun," Linden said. The study was funded by a "Progress for Patients" grant from the National Cancer Institute and the Avon Foundation. Joining Linden were researchers from the University of Washington, Fred Hutchinson Cancer Research Center and the University of Arizona Cancer Center.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Wild American Shrimp Board Agrees To Implement New Self-Funding Measures
3. Valley Health System Caregivers, Members of SEIU UHW, to Announce Endorsement of Measure G
4. People overestimate their self-reported sleep times compared to measures by a sleep test
5. Brain measurements could lead to better devices to move injured or artificial limbs
6. PA Health Department Suggests Measures to Reduce the Spread of MRSA
7. New Measures Improve Heart Care
8. New anemia measure predicts risk of death in dialysis patients
9. Nano-sized voltmeter measures electric fields deep within cells
10. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
11. AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... enrichment program serving the greater Venice, FL area, has initiated a fundraiser for ... a car accident just four days after Christmas. To support this beautiful child ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying ... , According to Perry A~, author of “Calcium Bentonite Clay” the health benefits of ... in balancing and detoxifying the body. , A former motivational speaker, Perry A~ has ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show where ... see the most incredible gardens and home improvement experts that attend this amazing show. ... - 700 14th St. Denver CO, is an exciting event that Performance Mobility has ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
(Date:2/8/2016)... CARLSBAD, Calif. , Feb. 8, 2016  HemaFlo Therapeutics, ... Office (USPTO) has issued US Patent Number 9,119,880 covering the ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ... technology." --> Dale Peterson , PhD, HemaFlo,s ... such a powerful technology." --> Dale ...
(Date:2/8/2016)... , Feb. 8, 2016  Astellas Pharma Inc. President and ... promotion of James Robinson as president, Americas Operations, ... in North and South America , effective ... US, representing the commercial organization in the United ... Masao Yoshida , who is retiring in ...
Breaking Medicine Technology: